抗中性粒细胞胞质抗体相关血管炎的多病共存:苏格兰纵向多中心数据链接研究
该研究基于苏格兰全国AAV队列(543例患者与2672例对照)发现,AAV患者在各时间点更易发生个体疾病,诊断后2年内风险尤其突出,骨质疏松风险最高(调整后发生率比8.0,95%CI 4.5-14.2)。AAV患者多病共存比例在1年时为23.0%、10年时为37.0%,均显著高于对照,且多病共存与医疗支出不成比例增加相关。
要点
- AAV患者诊断后2年内个体疾病风险最高,骨质疏松调整后发生率比达8.0。
- AAV患者1年多病共存率23.0%、10年37.0%,均显著高于一般人群。
- 多病共存与医疗支出不成比例增加相关,≥3种疾病者费用增加3.89倍。
核心结论
- AAV患者多病共存负担显著高于一般人群,且与医疗支出不成比例增加相关,提示需整体照护和早期筛查。
研究设计与样本
- 基于苏格兰全国AAV队列的纵向多中心数据链接研究,纳入1997—2017年诊断的543例AAV患者,按1:5匹配2672例一般人群对照,中位随访5.1年。
主要发现
- AAV患者在所有时间点更易发生个体疾病,诊断后<2年风险尤其突出,骨质疏松调整后发生率比最高(8.0,95%CI 4.5-14.2)。
- 诊断后1年,AAV患者23.0%与对照9.3%发生多病共存(P<0.0001);10年时分别为37.0%与17.3%(P<0.0001)。
- 多病共存与AAV患者医疗支出不成比例增加相关,≥3种疾病者费用较无疾病者增加3.89倍(95%CI 2.83-5.31,P<0.001)。
关键数值与推荐
- 多病共存定义为发生≥2种疾病。
- 预设个体疾病及多病共存的风险与关联采用修正Poisson回归、离散区间分析和卡方趋势检验分析。
- 多病共存与医疗支出的关系采用多变量线性回归分析。
临床怎么用
- 对AAV患者应关注多病共存的早期筛查,尤其是诊断后2年内。
- 临床管理需强调整体照护,并关注多病共存带来的医疗支出增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Antineutrophil cytoplasmic antibody-associated vasculitis (AAV) is considered a chronic, relapsing condition. To date, no studies have investigated multimorbidity in AAV nationally. This study was undertaken to characterize temporal trends in multimorbidity and report excess health care expenditures associated with multimorbidities in a national AAV cohort from Scotland. METHODS: Eligible patients with AAV were diagnosed between 1997 and 2017. Each patient was matched with up to 5 general population controls. Linked morbidity and health care expenditure data were retrieved from a Scottish national hospitalization repository and from published national cost data. Multimorbidity was defined as the development of ≥2 disorders. Prespecified morbidities, individually and together, were analyzed for risks and associations over time using modified Poisson regression, discrete interval analysis, and chi-square test for trend. The relationship between multimorbidities and health care expenditure was investigated using multivariate linear regression. RESULTS: In total, 543 patients with AAV (median age 58.7 years [range 48.9-68.0 years]; 53.6% male) and 2,672 general population controls (median age 58.7 years [range 48.9-68.0 years]; 53.7% male) were matched and followed up for a median of 5.1 years. AAV patients were more likely to develop individual morbidities at all time points, but especially <2 years after diagnosis. The highest proportional risk observed was for osteoporosis (adjusted incidence rate ratio 8.0, 95% confidence interval [95% CI] 4.5-14.2). After 1 year, 23.0% of AAV patients and 9.3% of controls had developed multimorbidity (P < 0.0001). After 10 years, 37.0% of AAV patients and 17.3% of controls were reported to have multimorbidity (P < 0.0001). Multimorbidity was associated with disproportionate increases in health care expenditures in AAV patients. Health care expenditure was highest for AAV patients with ≥3 morbidities (3.89-fold increase in costs, 95% CI 2.83-5.31; P < 0.001 versus no morbidities). CONCLUSION: These findings emphasize the importance of holistic care in patients with AAV, and may identify a potentially critical opportunity to consider early screening.
引用
- Sarica SH, Gallacher PJ, Dhaun N, et al. Multimorbidity in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Results From a Longitudinal, Multicenter Data Linkage Study. Arthritis Rheumatol. 2021. PMID: 33058567. doi:10.1002/art.41557
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。